Acadia Phramaceuticals Q3 revenue rises, lifts 2025 revenue guidance

Acadia Pharmaceuticals

05/11/2025 22:26

Overview

Acadia Q3 2025 revenue grows 11% yr/yr to $278.6 mln

Net income for Q3 2025 rises to $71.8 mln, reflecting tax benefit

Company updates 2025 guidance, raising high end for NUPLAZID and DAYBUE sales

Outlook

Acadia raises 2025 revenue guidance to $1.070 bln-$1.095 bln

Company expects NUPLAZID sales of $685 mln-$695 mln in 2025

Acadia forecasts DAYBUE sales of $385 mln-$400 mln for 2025

Result Drivers

NUPLAZID SALES GROWTH - Driven by 9% volume increase and higher net selling price

DAYBUE SALES EXPANSION - Boosted by field force expansion and named patient supply programs outside the U.S.

PIPELINE ADVANCEMENT - Initiation of Phase 2 and Phase 3 trials for new treatments

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Sales
$278.63 mln
Q3 EPS
$0.42
Q3 Net Income
$71.78 mln
Q3 Operating Expenses
$242.88 mln
Q3 Pretax Profit
$44.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for ACADIA Pharmaceuticals Inc is $29.00, about 24.7% above its November 4 closing price of $21.85

The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 35 three months ago

Press Release: ID:nBw6hX4PQa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)